UNIVERSITY OF PENNSYLVANIA OFFICE OF REGULATORY AFFAIRS 3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 Protocol #: INFORMED CONSENT WORKSHEET Is Element Addressed? No Waived Yes Provide Provide comme comme nt nt Elements Comments Required Elements Study design. Statement that the study involves research, an explanation of the purpose of the research, expected duration of the subject's participation, a description of the procedures followed, and identification of any procedure that is experimental, information about prior, similar, or related studies. Risks. Description of reasonably foreseeable risks and discomforts. Benefits. Description of benefits to the subject or others. Alternatives. Disclosure of appropriate alternative procedures or courses of treatment, if any, which may be advantageous to the subject. Confidentiality. A statement describing the extent to which confidentiality of records identifying the subject will be maintained. For investigational drug or device studies, a statement that FDA may review the records. Compensation. For research involving more than minimal risk, a statement that compensation will be provided for injury proximate to enrollment in the study. NOTE: • Include an explanation as to whether or not compensation was available if injury occurred. • If compensation is available when injury occurred, an explanation as to what it consisted of or where further information might be obtained. Contact. Whom to contact with questions about the research, and subjects’ rights and whom to contact in the event of a research-related injury including name or office and telephone numbers. Voluntary. A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits, the subject may withdraw at any time without penalty or loss of benefits. Additional Elements YES NO Waived Comment N/A If Waived, NO or N/A Unforeseeable risks. A statement that the treatment or procedure may cause risks to the subject (or embryo or fetus) which are currently unforeseeable. Page 1 of 3 Informed Consent Checklist Version: 8 May 2008 UNIVERSITY OF PENNSYLVANIA OFFICE OF REGULATORY AFFAIRS 3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 NOTE: Include this statement if the research involves investigational drugs or devices or the risk profile is not well known. Include if the research involves women and the risk profile is not well known. Termination. Anticipated circumstances under which the subject's participation may be terminated by the investigator. NOTE: Include if the investigator may terminate the subject’s participation without regard for the subject’s consent. Include the circumstances under which termination could occur. Additional costs. Additional costs to the subject that may result from participation in the research. NOTE: Include if the subject may incur any additional costs. Disclose the additional costs to the subject. Voluntary withdrawal. The consequences of a subject's decision to withdraw and procedures for orderly end of subject's participation. NOTE: Include if there are any potential adverse consequences of withdrawal (physical, social, economic, legal, or psychological). Disclose the potential consequences. Include any procedures the subject should follow to prevent harm. New findings. A statement that significant new findings developed during the course of research which may relate to the subject’s willingness to continue participation will be provided. NOTE: Include if the research will take place over a span of time in which significant new findings could occur that could alter a subject’s willingness to continue in the study. Number of subjects. The approximate number of subjects involved in the study. NOTE: Include if the number of subjects participating locally or on total might be important in the prospective subjects’ decision making processes. For example, clinical trials where there is little or no experience in humans or the numbers are very large and the safety profile may be better understood. Documentation of Informed Consent Informed consent must be documented in writing and signed and dated by the subject unless waived under HHS 45 CFR 46.117. Documentation may not be waived for FDA regulated research except under 21 CFR 50.23 Exculpatory Language No informed consent, written or oral, may include exculpatory language through which the subject or representative waives or appears to waive any legal rights, Page 2 of 3 Informed Consent Checklist Version: 8 May 2008 UNIVERSITY OF PENNSYLVANIA OFFICE OF REGULATORY AFFAIRS 3624 Market Street, Suite 301 S, Philadelphia, PA 19104-6006 or releases or appears to release the investigator, sponsor, institution, or its agents from liability for negligence. Conflicts of Interest Disclosure Include a disclosure of conflicts of interest involving Investigator and others engaged in research, if any. Payment for Participation Describe payment for participation and disbursement schedule. Where there is none, so state. Reporting Requirements Include statements regarding reporting requirements in accordance with PA law, for example, child abuse, communicable diseases. See Guidance on PA Law. HIPAA Authorization, if required, either within the informed consent document on in a stand alone Authorization For. List of PHI collected as part of the study Who may use disclose the information Who may receive the information Duration of authorization or no expiration Right to revoke authorization Reference to Notice of Privacy Practices Information disclosed outside covered entity may not be protected Page 3 of 3 Informed Consent Checklist Version: 8 May 2008